Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole.

Abstract

TWO PROTON pump inhibitors (PPIs), lansoprazole (Prevacid; TAP Pharmaceuticals Inc, Deerfield, Ill) and omeprazole (Prilosec; AstraZeneca, Wayne, Pa), are currently available commercially in the United States. Both agents are approved by the Food and Drug Administration for the treatment of duodenal and gastric ulcer, gastroesophageal reflux disease (GERD), eradication of Helicobacter pylori, and pathologic hypersecretory conditions. Lansoprazole is also approved for the prophylaxis of duodenal ulcer. In clinical trials, both agents have shown comparable safety and efficacy in treating acid-related peptic disorders.^1-3 In the treatment of GERD, a condition that requires prolonged gastric acid suppression, PPIs were found to be effective 78% to 90% of the time.^4,5